“Every man over 50 needs PSA screening.”
Screening can reduce prostate cancer deaths, but it also causes extra diagnoses and potential treatment harms. Age alone does not establish that every person should be screened.
PSA screening is a personal health decision, not an automatic requirement for every man over 50. The balance depends on cancer risk, health, life expectancy and preferences. Testing to investigate symptoms is a different use of PSA.
Screening can find slow-growing cancers that would never cause illness. Follow-up tests and treatment can have consequences, including urinary and sexual side effects.
Who might benefit from PSA screening to reduce prostate cancer deaths?
People with enough life expectancy to benefit may choose screening after discussing the trade-offs. In a large randomized trial of men aged 55-69, repeated invitations prevented about 2 prostate cancer deaths per 1,000 men over 23 years, while increasing cancer diagnoses.
Safety note: An elevated PSA does not by itself diagnose cancer. A low result cannot explain away concerning symptoms.
Talk to a healthcare professional if: Discuss risk and preferences with a clinician, especially with a strong family history, relevant inherited variants or other higher-risk circumstances.
Neither “everyone must test” nor “screening is useless” matches the research.
Have a screening discussion before deciding whether and how often to test.